Multivalent recombinant antibodies for treating hrv infections

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 16/46 (2006.01) A61K 39/385 (2006.01) A61K 39/395 (2006.01) A61P 31/14 (2006.01) C07K 16/28 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2313028

The present invention relates to high affinity multivalent recombinant antibodies and multivalent peptides against ICAM-1 and/or LDL receptor and pharmaceutical compositions containing such multivalent antibodies or multivalent peptides. The present invention also relates to methods of using such multivalent antibodies or multivalent peptides to prevent and treat human rhinovirus infection and diseases and pathological conditions associated therewith.

La présente invention concerne des anticorps de recombinaison multivalents à haute affinité et des peptides multivalents contre le récepteur d'ICAM-1 et/ou de LDL, ainsi que des compositions pharmaceutiques contenant ces anticorps multivalents ou peptides multivalents. La présente invention concerne également des méthodes d'utilisation de ces anticorps multivalents ou peptides multivalents pour la prévention et le traitement d'infections dues au rhinovirus humain ainsi que d'affections et de troubles pathologiques associés à ce dernier.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Multivalent recombinant antibodies for treating hrv infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multivalent recombinant antibodies for treating hrv infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent recombinant antibodies for treating hrv infections will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2081439

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.